Limits...
The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus.

Chmielnicka M, Woźniacka A, Torzecka JD - Postepy Dermatol Alergol (2014)

Bottom Line: However, the patient group demonstrated a significantly lower concentration of osteocalcin by up to 18.03%.A decreased osteoblast activity stimulates bone loss.The reduced level of osteocalcin, which is regarded as a marker for bone formation, and a simultaneously elevated RANK level reveal the promotion of osteoclast proliferation in patients treated with corticosteroids.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland. Head of Department: Prof. Anna Woźniacka MD, PhD.

ABSTRACT

Introduction: Pemphigus is a rare autoimmune blistering disease, which requires prolonged administration of corticosteroids at high doses. Although this therapy improves the health and lives of patients, it may have various side effects, for example osteoporosis.

Aim: To assess the concentration of osteoprotegerin (OPG), the soluble receptor activator of nuclear factor-κβ ligand (sRANKL) and osteocalcin in patients with pemphigus.

Material and methods: The study comprised a group of 29 patients with pemphigus (17 women and 12 men) aged between 23 years and 75 years treated from 1994 to 2009 in the Department of Dermatology and Venereology, Medical University of Lodz, as well as 24 healthy volunteers matched appropriately in terms of gender and age.

Results: In patients with pemphigus, the mean osteoprotegerin concentration was up to 16.46% higher than in the control group. The average RANKL concentration in serum of patients with pemphigus was 26.88% higher. However, the patient group demonstrated a significantly lower concentration of osteocalcin by up to 18.03%.

Conclusions: Under corticosteroid treatment, RANKL, which is released by osteoblasts, links with the RANK specific osteoclast receptor and stimulates osteoclastogenesis. This reaction can be blocked by osteoprotegerin, which is a competitive inhibitor to the same receptor site. A decreased osteoblast activity stimulates bone loss. The reduced level of osteocalcin, which is regarded as a marker for bone formation, and a simultaneously elevated RANK level reveal the promotion of osteoclast proliferation in patients treated with corticosteroids.

No MeSH data available.


Related in: MedlinePlus

Comparison of the mean levels of sRANKL in controls and patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4221354&req=5

Figure 0004: Comparison of the mean levels of sRANKL in controls and patients

Mentions: Concentrations of sRANKL ranged from 270.80 pmol/l to 997.30 pmol/l in pemphigus patients while they ranged from 213.50 pmol/l to 572.10 pmol/l in the control group. The mean concentration of this parameter was significantly higher in the corticosteroid-treated group (539.05 pmol/l) than in the control group (394.14 pmol/l). The difference was 26.88%, which was statistically significant (p < 0.001) (Table 4, Figure 4). No differences with regard to the gender of the subjects were found in these compared groups (patients/controls) (p > 0.05) (Tables 5 and 6, Figure 5). The mean concentrations of sRANKL in both women and men of the patient group were significantly higher than those found in their gender-compatible control group (p < 0.002 for men; p < 0.02 for women) (Figure 6). However, no statistically significant differences (p = 0.93) between the average concentration of sRANKL in group I (560.93 pmol/l) and II (525.68 pmol/l) have been found.


The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus.

Chmielnicka M, Woźniacka A, Torzecka JD - Postepy Dermatol Alergol (2014)

Comparison of the mean levels of sRANKL in controls and patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4221354&req=5

Figure 0004: Comparison of the mean levels of sRANKL in controls and patients
Mentions: Concentrations of sRANKL ranged from 270.80 pmol/l to 997.30 pmol/l in pemphigus patients while they ranged from 213.50 pmol/l to 572.10 pmol/l in the control group. The mean concentration of this parameter was significantly higher in the corticosteroid-treated group (539.05 pmol/l) than in the control group (394.14 pmol/l). The difference was 26.88%, which was statistically significant (p < 0.001) (Table 4, Figure 4). No differences with regard to the gender of the subjects were found in these compared groups (patients/controls) (p > 0.05) (Tables 5 and 6, Figure 5). The mean concentrations of sRANKL in both women and men of the patient group were significantly higher than those found in their gender-compatible control group (p < 0.002 for men; p < 0.02 for women) (Figure 6). However, no statistically significant differences (p = 0.93) between the average concentration of sRANKL in group I (560.93 pmol/l) and II (525.68 pmol/l) have been found.

Bottom Line: However, the patient group demonstrated a significantly lower concentration of osteocalcin by up to 18.03%.A decreased osteoblast activity stimulates bone loss.The reduced level of osteocalcin, which is regarded as a marker for bone formation, and a simultaneously elevated RANK level reveal the promotion of osteoclast proliferation in patients treated with corticosteroids.

View Article: PubMed Central - PubMed

Affiliation: Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland. Head of Department: Prof. Anna Woźniacka MD, PhD.

ABSTRACT

Introduction: Pemphigus is a rare autoimmune blistering disease, which requires prolonged administration of corticosteroids at high doses. Although this therapy improves the health and lives of patients, it may have various side effects, for example osteoporosis.

Aim: To assess the concentration of osteoprotegerin (OPG), the soluble receptor activator of nuclear factor-κβ ligand (sRANKL) and osteocalcin in patients with pemphigus.

Material and methods: The study comprised a group of 29 patients with pemphigus (17 women and 12 men) aged between 23 years and 75 years treated from 1994 to 2009 in the Department of Dermatology and Venereology, Medical University of Lodz, as well as 24 healthy volunteers matched appropriately in terms of gender and age.

Results: In patients with pemphigus, the mean osteoprotegerin concentration was up to 16.46% higher than in the control group. The average RANKL concentration in serum of patients with pemphigus was 26.88% higher. However, the patient group demonstrated a significantly lower concentration of osteocalcin by up to 18.03%.

Conclusions: Under corticosteroid treatment, RANKL, which is released by osteoblasts, links with the RANK specific osteoclast receptor and stimulates osteoclastogenesis. This reaction can be blocked by osteoprotegerin, which is a competitive inhibitor to the same receptor site. A decreased osteoblast activity stimulates bone loss. The reduced level of osteocalcin, which is regarded as a marker for bone formation, and a simultaneously elevated RANK level reveal the promotion of osteoclast proliferation in patients treated with corticosteroids.

No MeSH data available.


Related in: MedlinePlus